Yair Herishanu

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ...

Venetoclax bij recidief/refractaire CLL: MURANO/CLL14 analyse

Acalabrutinib met of zonder obinutuzumab versus chlorambucil-obinutuzumab bij onbehandelde CLL: ELEVATE-TN fase III